Interactions of anti-Parkinson drug benserazide with Zn(II), Cu(II), Fe(II) ions.

Lukasz Szyrwiel, József S Pap, Wieslaw Malinka, Zbigniew Szewczuk, Aleksandra Kotynia, Justyna Brasun

Department of Chemistry of Drugs, Wrocław Medical University, ul. Borowska 211, 50-552 Wrocław, Poland; CNRS/UPPA, LCABIE, UMR5254, Hélioparc, 2, av. Pr. Angot, F-64053 Pau, France. lukasz.szyrwiel@am.wroc.pl

Journal of pharmaceutical and biomedical analysis 2013 Mar 25

filter terms:

One of the treatments of Parkinson disease is based on increasing the brain dopamine level by L-DOPA (LD) applications. To prevent the peripheral degradation of levodopa, another drug, benserazide is applied. On the other hand, during this neurodegenerative disease changes in the homeostasis of metals are observed and the increasing brain zinc levels are postulated to have therapeutic effects. Here we present studies on interactions of Zn(II), Cu(II), Fe(II) ions with benserazide and with benserazide/levodopa in ternary system. By applying mass spectrometry and UV-vis methods we describe the interactions between selected metal ions and the drug additives in the investigated systems. The results show forming of equimolar complexes in the binary and ternary systems. Copyright © 2012 Elsevier B.V. All rights reserved.

Citation

Lukasz Szyrwiel, József S Pap, Wieslaw Malinka, Zbigniew Szewczuk, Aleksandra Kotynia, Justyna Brasun. Interactions of anti-Parkinson drug benserazide with Zn(II), Cu(II), Fe(II) ions. Journal of pharmaceutical and biomedical analysis. 2013 Mar 25;76:36-43